AVXL240726P4000
- 0.04
- 0.000.00%
Anavex Life Sciences Newsroom
Cassava Alzheimer's Drug Set for First Phase 3 Readout by December 2024
JonesTrading Maintains Anavex Life Sciences(AVXL.US) With Buy Rating, Maintains Target Price $15
JonesTrading analyst Soumit Roy maintains $Anavex Life Sciences(AVXL.US)$ with a buy rating, and maintains the target price at $15.According to TipRanks data, the analyst has a success rate of 23.2%
Express News | EF Hutton Initiates Coverage On Anavex Life Sciences With Buy Rating, Announces Price Target of $46
CrossFirst Bankshares Posts Q2 Earnings, Joins Owens & Minor, Reddit And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 40 points on Tuesday.Shares of CrossFirst Bankshares, Inc. (NASDAQ:CFB) fell sharply in today's pre-market trading
Why Match Group Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Shares of Match Group, Inc. (NASDAQ:MTCH) rose sharply in today's pre-market trading.Starboard Value has taken a keen interest in Match Group. The hedge fund has accumulated a stake of over 6.5% in
Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of
Anavex Life Sciences(AVXL.US) Director Buys US$10,319.4 in Common Stock
$Anavex Life Sciences(AVXL.US)$ Director Donhauser Peter D.O. purchased 2,835 shares of common stock on Jun 14, 2024 at an average price of $3.64 for a total value of $10,319.4.Source: Announcement Wh
H.C. Wainwright Maintains Anavex Life Sciences(AVXL.US) With Buy Rating, Maintains Target Price $40
H.C. Wainwright analyst Ram Selvaraju maintains $Anavex Life Sciences(AVXL.US)$ with a buy rating, and maintains the target price at $40.According to TipRanks data, the analyst has a success rate of 3
Lilly's Donanemeb, Remternetug Set to Dominate Alzheimer's Treatment by 2030
GSK, Boston Beer And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 0.5% on Monday.Shares of GSK plc (NYSE:GSK) fell sharply in today's pre-market trading after the company said it will
Anavex Life Sciences Corp.'s (NASDAQ:AVXL) 14% Loss Last Week Hit Both Individual Investors Who Own 59% as Well as Institutions
Key Insights Anavex Life Sciences' significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public A total of 25 investors have a majorit
Anavex Life Sciences Expands Leadership Team; Shares Rise
Anavex Life Sciences (AVXL) shares were up more than 3% in recent Wednesday trading after the company reported new appointments to its leadership team. The company hired Juan Carlos Lopez-Talavera as
Express News | Anavex Life Sciences Announces Expansion of Leadership Team
Anavex Life Sciences (NASDAQ:AVXL) Is In A Good Position To Deliver On Growth Plans
Anavex Life Sciences(AVXL.US) Director Buys US$22,600 in Common Stock
$Anavex Life Sciences(AVXL.US)$ Director Thomas Steffen purchased 5,000 shares of common stock on May 15, 2024 at an average price of $4.52 for a total value of $22,600.Source: Announcement What is st
Anavex Life Sciences (AVXL) Upgraded to Buy: What Does It Mean for the Stock?
Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ
NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of
Anavex Life Sciences Corp. (NASDAQ:AVXL) Q2 2024 Earnings Call Transcript
Express News | HC Wainwright & Co. Reiterates Buy on Anavex Life Sciences, Maintains $40 Price Target
Anavex Life Sciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 938.96% HC Wainwright & Co. → $40 Reiterates Buy → Buy 01/03/2024 938.96% HC Wainwright & Co. $